B. Sørensen

发表

Factor VIIa analogue (V158D/E296V/M298Q‐FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A

J. Ingerslev, B. Sørensen, E. Persson, 2007, British journal of haematology.

Fibrinogen as a Hemostatic Agent

B. Sørensen, J. Foley, O. H. Larsen, 2012, Seminars in Thrombosis & Hemostasis.

Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

R. Rossaint, D. Spahn, P. Innerhofer, 2011, Critical care.

Correction: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

R. Rossaint, D. Spahn, P. Innerhofer, 2011, Critical Care.

Rationale for individualizing haemophilia care

G. Auerswald, G. Benson, T. Lambert, 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Diagnostic Performance and Therapeutic Consequence of Thromboelastometry Activated by Kaolin versus a Panel of Specific Reagents

J. Ingerslev, B. Sørensen, O. H. Larsen, 2011, Anesthesiology.

A comparison of fibrinogen measurement methods with fibrin clot elasticity assessed by thromboelastometry, before and after administration of fibrinogen concentrate in cardiac surgery patients

H. Schöchl, C. Solomon, B. Sørensen, 2011, Transfusion.

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa

J. Ingerslev, B. Sørensen, 2004, Journal of thrombosis and haemostasis : JTH.

Thromboelastography and recombinant factor VIIa-hemophilia and beyond.

J. Ingerslev, B. Sørensen, 2004, Seminars in hematology.

Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.

J. Ingerslev, B. Sørensen, C. Fenger-Eriksen, 2008, British journal of anaesthesia.

Emerging treatment strategies for trauma‐induced coagulopathy

B. Sørensen, D. Fries, 2012, The British journal of surgery.

Monitoring bypassing agent therapy – a prospective crossover study comparing thromboelastometry and thrombin generation assay

G. Tjønnfjord, H. Tran, P. Andre Holme, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction.

G. Kenet, B. Sørensen, A. Sehgal, 2020, Blood cells, molecules & diseases.

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

S. Milstein, K. G. Rajeev, M. Manoharan, 2015, Nature Medicine.

Pharmacokinetic and pharmacodynamic properties of plasma‐derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study

S. Rangarajan, B. Sørensen, J. Alamelu, 2014, Journal of thrombosis and haemostasis : JTH.

FXIII: mechanisms of action in the treatment of hemophilia A

B. Sørensen, J. Foley, C. Rea, 2014, Journal of thrombosis and haemostasis : JTH.

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts

J. Ingerslev, B. Sørensen, O. H. Larsen, 2011, British journal of haematology.

An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A

D. Bevan, B. Sørensen, J. Foley, 2014, Annals of Hematology.

Platelet activation and aggregation: the importance of thrombin activity—A laboratory model

J. Ingerslev, B. Sørensen, O. H. Larsen, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery.

C. Solomon, B. Sørensen, N. Rahe-meyer, 2011, Thrombosis research.

Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation

J. Ingerslev, B. Sørensen, K. Christiansen, 2003, Journal of thrombosis and haemostasis : JTH.

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

A. Akinc, D. Bevan, K. Pasi, 2017, The New England journal of medicine.

Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio

B. Sørensen, T. Larsen, T. Christensen, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia

B. Sørensen, L. Poulsen, J. Ingerslev, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis‐prone patients

J. Ingerslev, B. Sørensen, K. Christiansen, 2006, Scandinavian journal of clinical and laboratory investigation.

Global Laboratory Assays in Hemophilia

G. Young, B. Sørensen, 2014 .

Global haemostasis and point of care testing

C. Négrier, M. Shima, A. Srivastava, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review

D. Spahn, J. Hess, B. Sørensen, 2011, Critical care.

Fibrinogen concentrate – a potential universal hemostatic agent

J. Ingerslev, B. Sørensen, C. Fenger-Eriksen, 2009, Expert opinion on biological therapy.

Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects

J. C. Sørensen, J. Ingerslev, B. Sørensen, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Rational and timely haemostatic interventions following cardiac surgery - coagulation factor concentrates or blood bank products.

V. Hjortdal, J. Greisen, J. Ingerslev, 2017, Thrombosis research.

The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery.

P. T. Onundarson, B. Sørensen, B. Gudmundsdottir, 2009, Thrombosis research.

Whole blood laboratory model of thrombocytopenia for use in evaluation of hemostatic interventions

J. Ingerslev, B. Sørensen, O. H. Larsen, 2007, Annals of Hematology.

Evaluation of coagulation kinetics using thromboelastometry—methodologic influence of activator and test medium

J. Ingerslev, B. Sørensen, O. H. Larsen, 2010, Annals of Hematology.

Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue

J. Ingerslev, B. Sørensen, E. Persson, 2009, British journal of haematology.

Improved point-of-care identification of hyperfibrinolysis is needed.

J. Ingerslev, B. Sørensen, O. H. Larsen, 2012, Thrombosis research.

A direct thrombin inhibitor studied by dynamic whole blood clot formation

J. Ingerslev, B. Sørensen, 2006, Thrombosis and Haemostasis.

Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients

J. Ingerslev, B. Sørensen, S. Brandsborg, 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Effects of Fibrinogen Concentrate as First-line Therapy during Major Aortic Replacement Surgery: A Randomized, Placebo-controlled Trial

A. Hanke, C. Solomon, B. Sørensen, 2013, Anesthesiology.

Comparison of Whole Blood Fibrin-Based Clot Tests in Thrombelastography and Thromboelastometry

H. Schöchl, C. Solomon, B. Sørensen, 2012, Anesthesia and analgesia.

Role of recombinant activated factor VII as hemostatic support in orthopedic surgery

J. Ingerslev, B. Sørensen, 2006 .

Citrate artificially masks the haemostatic effect of recombinant factor VIIa in dilutional coagulopathy

J. Ingerslev, B. Sørensen, C. Fenger-Eriksen, 2009, Annals of Hematology.

Parallel use of by‐passing agents in haemophilia with inhibitors: a critical review

J. Ingerslev, B. Sørensen, 2011, British journal of haematology.

Future pharmacological strategies in management of Haemophilia.

B. Sørensen, 2010, Thrombosis research.

Reduced clot-stability during the first 6 hours after aneurysmal subarachnoid haemorrhage--a prospective case-control study.

B. Sørensen, J. Astrup, J. Nielsen, 2012, Thrombosis research.

A critical evaluation of cryoprecipitate for replacement of fibrinogen

B. Sørensen, D. Bevan, 2010, British journal of haematology.

Fibrinogen concentrate and cryoprecipitate but not fresh frozen plasma correct low fibrinogen concentrations following in vitro haemodilution.

B. Sørensen, C. Rea, C. Fenger-Eriksen, 2013, Thrombosis research.

Levels of fibrinogen and thromboelastometry fibrin polymerisation following treatment with desmopressin (DDAVP).

B. Sørensen, G. Moore, C. Fenger-Eriksen, 2012, Thrombosis research.

The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding.

B. Sørensen, O. H. Larsen, C. Rea, 2011, Thrombosis research.

Fibrinogenconcentrate- apotentialuniversalhemostatic agent

J. Ingerslev, B. Sørensen, C. Fenger-Eriksen, 2009 .

Coagulopathy induced by colloid plasma expanders – search for an efficacious haemostatic intervention

J. Ingerslev, B. Sørensen, C. Fenger-Eriksen, 2006, Acta anaesthesiologica Scandinavica.

Fibrinogen estimates are influenced by methods of measurement and hemodilution with colloid plasma expanders

S. Rangarajan, J. Ingerslev, B. Sørensen, 2010, Transfusion.

Temporal changes in clot lysis and clot stability following tranexamic acid in cardiac surgery

V. Hjortdal, J. Ingerslev, B. Sørensen, 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients

P. Simioni, B. Sørensen, L. Spiezia, 2008, Thrombosis and Haemostasis.

Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate.

J. Ingerslev, B. Sørensen, C. Fenger-Eriksen, 2005, British journal of anaesthesia.

Complementary effect of fibrinogen and rFVIIa on clotting ex vivo in Bernard-Soulier syndrome and combined use during three deliveries

P. T. Onundarson, J. Ingerslev, B. Sørensen, 2014, Platelets.

No excess surgical blood loss in patients with acquired type 2A von Willebrand disease

S. Johnsen, B. Sørensen, C. Fenger-Eriksen, 2011, Scandinavian cardiovascular journal : SCJ.

Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors

T. Ueland, G. Tjønnfjord, P. Holme, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Standardization of thromboelastography: a report from the TEG‐ROTEM working group

M. Othman, G. Young, G. Kenet, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Coagulopathy during Induced Severe Intracranial Hypertension in a Porcine Donor Model

J. Ingerslev, B. Sørensen, C. Fenger-Eriksen, 2009, Anesthesiology.

Long‐standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age‐matched Danish and Russian patients

S. Lethagen, J. Ingerslev, B. Sørensen, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.

Guy Young, C. Négrier, N. Key, 2013, Blood.

Current treatment of von Willebrand’s disease

J. Ingerslev, B. Sørensen, L. Poulsen, 2004, Hämostaseologie.

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

A. Akinc, D. Bevan, K. Pasi, 2015 .

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

A. Strahs, A. Akinc, B. Sørensen, 2014 .

Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients

V. Jiménez‐Yuste, G. Benson, T. Lambert, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Laboratory Assays to Predict Response to Bypassing Agents

C. Négrier, B. Sørensen, 2011 .

Replacement therapy for bleeding episodes in factor VII deficiency

G. Mariani, G. Auerswald, G. Di Minno, 2012, Thrombosis and Haemostasis.

Inhibitors to factor VII in congenital factor VII deficiency

G. Mariani, M. Pinotti, M. Karimi, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors to factor VII and in congenital factor VII deficiency

G. Mariani, M. Pinotti, M. Napolitano, 2014 .

A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B

Creagh, A. Akinc, D. Bevan, 2016 .

Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

D. Lillicrap, B. Sørensen, J. Foley, 2012, Blood.

Clinical phenotype in heterozygote and biallelic Bernard‐Soulier syndrome—A case control study

P. T. Onundarson, M. K. Magnússon, J. Ingerslev, 2015, American journal of hematology.

Factor XIII in the treatment of hemophilia A.

B. Sørensen, J. Foley, C. Rea, 2012, The New England journal of medicine.

Hypercoagulation following brain death cannot be reversed by the neutralization of systemic tissue factor.

S. Høyer, B. Sørensen, C. Fenger-Eriksen, 2013, Thrombosis research.

International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy

Thomas D Christensen, B. Sørensen, Torben B Larsen, 2009, Thrombosis and Haemostasis.

Emotional or evidence-based medicine: is there a moral tragedy in haemostatic therapy?

D. Spahn, J. Hess, B. Sørensen, 2011, Critical Care.

Biological Explanation of Clinically Observed Elevation of TFPI Plasma Levels After Treatment with TFPI-Antagonistic Aptamer BAX 499

H. Ehrlich, R. Pachlinger, B. Ewenstein, 2012 .

Liquid Dispersion, Mass Transport, and Chemical Reaction in Supported Liquid Phase Catalysts for SO2Oxidation

J. Villadsen, B. Sørensen, H. Livbjerg, 1975 .

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

M. Manoharan, D. Salant, K. Charissé, 2014 .

Feasibility of LMW Heparin Prophylaxis for Management of Thrombophilia Investigation in Patients on Oral Anticoagulation Therapy

J. Ingerslev, B. Sørensen, G. L. Nielsen, 2001, Thrombosis and Haemostasis.

New approaches in the measurement of coagulation

G. Castaman, J. Ingerslev, B. Sørensen, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

New approaches for measuring coagulation

S. Béguin, P. Bucciarelli, J. Ingerslev, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Fibrinogen concentrate for management of bleeding

B. Sørensen, B. Sørensen, N. Rahe-meyer, 2011, Journal of thrombosis and haemostasis : JTH.

Tailoring haemostatic treatment to patient requirements – an update on monitoring haemostatic response using thrombelastography

J. Ingerslev, B. Sørensen, B. Sørensen, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial

J. Ingerslev, B. Sørensen, C. Fenger-Eriksen, 2009, Journal of thrombosis and haemostasis : JTH.

Mechanisms of hydroxyethyl starch‐induced dilutional coagulopathy